
REGENXBIO Inc.: updates and filings
Price
$7.18
November 19, 2026Market cap $475M
What Ploutos Investor adds for REGENXBIO
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 16, 2026Officer or director changeForm8-K
- Oct 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 23, 2026Material agreement enteredForm8-K
- Aug 25, 2026Officer or director changeForm8-K
- Aug 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 20, 2026Other material eventsForm8-K
- Jul 6, 2026Filing (amendment)FormSC TO-I/A
- Jul 1, 2026Filing (amendment)FormSC TO-I/A
- Jun 29, 2026Other material eventsForm8-K
- Jun 4, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 3, 2026FilingFormSC TO-I
- Jun 3, 2026Shareholder vote, other material eventsForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 14, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 14, 2026Additional annual meeting materialFormDEFA14A
- Apr 14, 2026Annual meeting proxy statementFormDEF 14A
- Apr 3, 2026Preliminary proxy statementFormPRE 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 16, 2026 | 8-K | Officer or director change | Document |
| Oct 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 23, 2026 | 8-K | Material agreement entered | Document |
| Aug 25, 2026 | 8-K | Officer or director change | Document |
| Aug 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 20, 2026 | 8-K | Other material events | Document |
| Jul 6, 2026 | SC TO-I/A | Filing (amendment) | Document |
| Jul 1, 2026 | SC TO-I/A | Filing (amendment) | Document |
| Jun 29, 2026 | 8-K | Other material events | Document |
| Jun 4, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 3, 2026 | SC TO-I | Filing | Document |
| Jun 3, 2026 | 8-K | Shareholder vote, other material events | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 14, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 14, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 14, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 3, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 7, 2013.
The full analysis
What do REGENXBIO's filings show?
The filings are where every one of REGENXBIO's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.